Scarica l'app Stockscreener
47.42
2.13%
-1.03
Dopo l'orario di chiusura:
47.47
0.05
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$48.45
Aprire:
$47.685
Volume 24 ore:
12.23M
Relative Volume:
0.60
Capitalizzazione di mercato:
$210.86B
Reddito:
$46.77B
Utile/perdita netta:
$15.45B
Rapporto P/E:
13.67
EPS:
3.468
Flusso di cassa netto:
$4.40B
1 W Prestazione:
-4.34%
1M Prestazione:
-21.85%
6M Prestazione:
-12.67%
1 anno Prestazione:
-43.37%
Intervallo 1D:
$47.03
$47.75
Intervallo di 1 settimana:
$47.03
$49.85
Portata 52W:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
47.42 | 215.44B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
1,009.52 | 965.26B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.49 | 595.03B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.81 | 396.51B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
204.20 | 323.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
162.67 | 312.78B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly - The Motley Fool
Novo Nordisk stock forecast: Analysts mixed on Q4 earnings & 2026 guidance - Capital.com
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Novo Nordisk Balances Oral Wegovy Launch With Legal Fight On Compounds - Sahm
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm
FDA Crackdown Reshapes Wegovy Competition And Risks For Novo Nordisk Investors - Sahm
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz
Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz
Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm
Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz
Is Novo Nordisk Stock a Bargain Right Now? - Finviz
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):